SCHEMBL798091

SCHEMBL798091

CC(C)(C)C1OCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8610502 0.97
SCHEMBL10598577 0.87
SCHEMBL10130554 0.87
SCHEMBL12213701 0.74
SCHEMBL12809010 0.74
SCHEMBL3550832 0.73
SCHEMBL11681711 0.73
SCHEMBL22339883 0.73
SCHEMBL27967889 0.73
SCHEMBL6868995 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216346-A1 Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same THE WISTAR INST (US) 2024-07-04 US disclosed
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 US disclosed
US-20240018182-A1 GLUCOCORTICOID RECEPTOR AGONISTS ELI LILLY AND COMPANY 2024-01-18 US disclosed
US-11833137-B2 Substituted chromenones, IRE1 inhibitors, and methods of using same THE WISTAR INSTITUTE (US) 2023-12-05 US disclosed
US-20230373963-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2023-11-23 US disclosed
US-20230373963-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2023-11-23 US disclosed
US-20230355599-A1 BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE NURIX THERAPEUTICS, INC. 2023-11-09 US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 US disclosed
US-11787834-B2 Glucocorticoid receptor agonists ELI LILLY AND COMPANY (US) 2023-10-17 US disclosed
US-20230212186-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2023-07-06 US disclosed
US-20080227851-A1 LAULIMALIDE AND LAULIMALIDE ANALOGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-09-18 US disclosed
US-20080227851-A1 LAULIMALIDE AND LAULIMALIDE ANALOGS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-09-18 US disclosed
US-20080176840-A1 e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections SYNTA PHARMACEUTICALS CORP 2008-07-24 US disclosed
US-20080171888-A1 Process for making spirolactone compounds MERCK SHARP & DOHME CORP. 2008-07-17 US disclosed
US-20070225292-A1 Therapeutic Compounds: Pyridine as Scaffold ASTRAZENECA AB (SE) 2007-09-27 US disclosed
US-7273866-B2 2-aryl thiazole derivatives as KCNQ modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-25 US disclosed
US-20070219254-A1 Therapeutic Compounds: Pyridine N-Oxide Scaffold ASTRAZENECA AB (SE) 2007-09-20 US disclosed
EP-1597246-A2 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2005-11-23 EP disclosed
WO-2004074270-A2 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2004-09-02 WO disclosed
EP-0586378-B1 NOVEL PLATINUM(II) COMPLEX AND PROCESSES FOR PREPARING THE SAME SUNKYONG IND LTD (KR) 1998-09-23 EP disclosed